Identifying Factors Associated with the Efficacy of Lasmiditan 50 mg as an Acute Treatment for Migraine Attacks Under Various Dosing Conditions in Real-World Clinical Practice

<b>Background/Objectives</b>: Lasmiditan is a newly developed drug for the acute treatment of migraine attacks, but factors associated with its efficacy remain unclear. This study aimed to confirm the efficacy of lasmiditan started at 50 mg under various dosing conditions and identify factors associ...

Descrición completa

Detalles Bibliográficos

Principais autores:	Takafumi Tanei, Shun Yamamoto, Satoshi Maesawa, Yusuke Nishimura, Tomotaka Ishizaki, Yoshitaka Nagashima, Yoshiki Ito, Miki Hashida, Takahiro Suzuki, Hajime Hamasaki, Toshihiko Wakabayashi, Ryuta Saito
Formato:	Artigo
Idioma:	Inglês
Publicado:	MDPI AG 2025-04-01
Series:	Neurology International
Assuntos:	lasmiditan migraine 50 mg
Acceso en liña:	https://www.mdpi.com/2035-8377/17/5/62
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!